These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29508305)

  • 21. Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis.
    Jamois C; Gibiansky L; Chavanne C; Cheu M; Lehane PB; Pordeli P; Melega S; Gaudreault J
    Clin Transl Sci; 2022 Sep; 15(9):2172-2183. PubMed ID: 35765176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
    Gause AM; Rubbert-Roth A;
    Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis.
    Iudici M; Quartier P; Terrier B; Mouthon L; Guillevin L; Puéchal X
    Orphanet J Rare Dis; 2016 Oct; 11(1):141. PubMed ID: 27770813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.
    Harigai M; Tsutsumino M; Takada H; Nagasaka K
    Korean J Intern Med; 2019 May; 34(3):492-503. PubMed ID: 30613065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
    Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
    Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus.
    Kapoor T; Mahadeshwar P; Hui-Yuen J; Quinnies K; Tatonetti N; Gartshteyn Y; Guo C; Geraldino-Pardilla L; Askanase AD
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32513809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab induction and reinduction in granulomatosis with polyangiitis and microscopic polyangiitis: A retrospective multicenter study in Taiwan.
    Hsieh TY; Chen MH; Wu CC; Hong WJ; Lu CH; Lu CC; Lu LY; Hsieh SC; Tsai CY; Wu CS;
    Int J Rheum Dis; 2023 Dec; 26(12):2441-2449. PubMed ID: 37784228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.
    Focosi D; Tuccori M; Maggi F
    Rev Med Virol; 2019 Nov; 29(6):e2077. PubMed ID: 31369199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late-onset neutropenia after rituximab in ANCA-associated vasculitis.
    Knight A; Sundström Y; Börjesson O; Bruchfeld A; Malmström V; Gunnarsson I
    Scand J Rheumatol; 2016 Oct; 45(5):404-7. PubMed ID: 26948245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis under salazosulfapyridine treatment].
    Okazaki T; Kodama D; Yamadera M; Sugiyama Y; Tsuji H; Nishida F; Ooka Y; Nakamichi K; Hashikawa K; Yanagihara T
    Rinsho Shinkeigaku; 2021 Dec; 61(12):833-838. PubMed ID: 34789625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2009 Dec; 60(12):3761-5. PubMed ID: 19950261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.
    Bharat A; Xie F; Baddley JW; Beukelman T; Chen L; Calabrese L; Delzell E; Grijalva CG; Patkar NM; Saag K; Winthrop KL; Curtis JR
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):612-5. PubMed ID: 22162369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction.
    Willott RH; Sunman W; Munshi SK
    Age Ageing; 2016 Jul; 45(4):564-5. PubMed ID: 27056083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis].
    de Groot K; Aries PM; Haubitz M; Hellmich B; Lamprecht P; Thiel J
    Dtsch Med Wochenschr; 2020 Jan; 145(1):40-46. PubMed ID: 31914468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.
    Arkema EV; van Vollenhoven RF; Askling J;
    Ann Rheum Dis; 2012 Nov; 71(11):1865-7. PubMed ID: 22739991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of rituximab in rheumatic diseases.
    Rath E; Zwerina J; Oppl B; Nell-Duxneuner V
    Wien Med Wochenschr; 2015 Jan; 165(1-2):28-35. PubMed ID: 25676699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
    Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis.
    Morgenstern LB; Pardo CA
    J Rheumatol; 1995 Aug; 22(8):1593-5. PubMed ID: 7473491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.